European Commission launches a multi-stakeholder consultation to improve the clinical trials of advanced therapy medicinal products

Published 6 September 2018

Advanced Therapy Medicinal Products (ATMPs) are novel approaches for treating multiple diseases. ATMPs include Gene and Cell therapy medicinal products as well as Tissue engineered products. Wider implementation of these requires thorough design and execution of clinical trials. However, their complex and innovative nature can pose numerous challenges.

To overcome these, the European Commission is launching an online public consultation on the draft guidelines on good clinical practice for ATMPs. It targets small and medium-sized enterprises (SMEs), academia, hospitals and patient organisations. The comments are invited to be sent by 31 October 2018. You can visit this link for more information.